Lynette F. Smith

Array ( [id] => 20348458 [patent_doc_number] => 20250345310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => MODULATORS OF TNF-ALPHA ACTIVITY [patent_app_type] => utility [patent_app_number] => 19/287701 [patent_app_country] => US [patent_app_date] => 2025-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19287701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19948310 [patent_doc_number] => 12319657 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-03 [patent_title] => Solid state crystalline forms of a selective potassium channel modulator [patent_app_type] => utility [patent_app_number] => 19/094370 [patent_app_country] => US [patent_app_date] => 2025-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 46 [patent_no_of_words] => 38168 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19094370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19948310 [patent_doc_number] => 12319657 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-03 [patent_title] => Solid state crystalline forms of a selective potassium channel modulator [patent_app_type] => utility [patent_app_number] => 19/094370 [patent_app_country] => US [patent_app_date] => 2025-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 46 [patent_no_of_words] => 38168 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19094370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328376 [patent_doc_number] => 12458633 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Treatment of migraine [patent_app_type] => utility [patent_app_number] => 19/055918 [patent_app_country] => US [patent_app_date] => 2025-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13816 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19055918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328375 [patent_doc_number] => 12458632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Treatment of migraine [patent_app_type] => utility [patent_app_number] => 19/042453 [patent_app_country] => US [patent_app_date] => 2025-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14737 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19042453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328375 [patent_doc_number] => 12458632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Treatment of migraine [patent_app_type] => utility [patent_app_number] => 19/042453 [patent_app_country] => US [patent_app_date] => 2025-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14737 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19042453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023094 [patent_doc_number] => 20250161316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => USE OF REBOXETINE TO TREAT NARCOLEPSY [patent_app_type] => utility [patent_app_number] => 19/024709 [patent_app_country] => US [patent_app_date] => 2025-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19024709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023094 [patent_doc_number] => 20250161316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => USE OF REBOXETINE TO TREAT NARCOLEPSY [patent_app_type] => utility [patent_app_number] => 19/024709 [patent_app_country] => US [patent_app_date] => 2025-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19024709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897802 [patent_doc_number] => 12275706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 18/958628 [patent_app_country] => US [patent_app_date] => 2024-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 9948 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18958628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798863 [patent_doc_number] => 20250064788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => TREATMENT OF MIGRAINE [patent_app_type] => utility [patent_app_number] => 18/945079 [patent_app_country] => US [patent_app_date] => 2024-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18945079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19960278 [patent_doc_number] => 12329750 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Treatment of migraine [patent_app_type] => utility [patent_app_number] => 18/924415 [patent_app_country] => US [patent_app_date] => 2024-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8021 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18924415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19752724 [patent_doc_number] => 20250041289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => DOSING REGIMEN FOR INJECTABLE CETIRIZINE [patent_app_type] => utility [patent_app_number] => 18/919625 [patent_app_country] => US [patent_app_date] => 2024-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18919625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691177 [patent_doc_number] => 20250009722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => TREATMENT OF MIGRAINE [patent_app_type] => utility [patent_app_number] => 18/889824 [patent_app_country] => US [patent_app_date] => 2024-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18889824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554783 [patent_doc_number] => 20240366575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => TREATMENT OF MIGRAINE [patent_app_type] => utility [patent_app_number] => 18/776516 [patent_app_country] => US [patent_app_date] => 2024-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18776516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816671 [patent_doc_number] => 20250074878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE [patent_app_type] => utility [patent_app_number] => 18/767083 [patent_app_country] => US [patent_app_date] => 2024-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18767083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212540 [patent_doc_number] => 12409174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases [patent_app_type] => utility [patent_app_number] => 18/764612 [patent_app_country] => US [patent_app_date] => 2024-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 13468 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212540 [patent_doc_number] => 12409174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases [patent_app_type] => utility [patent_app_number] => 18/764612 [patent_app_country] => US [patent_app_date] => 2024-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 13468 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256075 [patent_doc_number] => 12428418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Pyrrolopyridine-aniline compounds for treatment of dermal disorders [patent_app_type] => utility [patent_app_number] => 18/745768 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 36985 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256075 [patent_doc_number] => 12428418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Pyrrolopyridine-aniline compounds for treatment of dermal disorders [patent_app_type] => utility [patent_app_number] => 18/745768 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 36985 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931699 [patent_doc_number] => 12304896 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Highly purified pharmaceutical grade tasimelteon [patent_app_type] => utility [patent_app_number] => 18/741969 [patent_app_country] => US [patent_app_date] => 2024-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1496 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18741969 [rel_patent_id] =>[rel_patent_doc_number] =>)